A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia.

Abstract

CX516, a positive modulator of the glutamatergic alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor, improves performance in tasks requiring learning and memory in animals. CX516 was added to clozapine in 4-week, placebo-controlled, dose-finding (N = 6) and fixed-dose (N = 13) trials. CX516 was tolerated well and was associated with moderate to large, between-group effect sizes compared with placebo, representing improvement in measures of attention and memory. These preliminary results suggest that CX516 and other "ampakines" hold promise for the treatment of schizophrenia.

• Authors: D C Goff, L Leahy, I Berman, T Posever, L Herz, A C Leon, S A Johnson, G Lynch
• Journal: Journal of clinical psychopharmacology (J Clin Psychopharmacol) Vol. 21 Issue 5 Pg. 484-7 (Oct 2001) ISSN: 0271-0749 [Print] United States
• PMID: 11593073 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• 1-(quinoxalin-6-ylcarbonyl)piperidine
• Antipsychotic Agents
• Dioxoles
• Piperidines
• Clozapine

Topics

• Adult
• Antipsychotic Agents (administration & dosage, therapeutic use)
• Attention (drug effects)
• Clozapine (administration & dosage, therapeutic use)
• Cognition (drug effects)
• Dioxoles (administration & dosage, therapeutic use)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Drug Therapy, Combination
• Female
• Humans
• Male
• Memory (drug effects)
• Middle Aged
• Pilot Projects
• Piperidines (administration & dosage, therapeutic use)
• Psychological Tests
• Schizophrenia (drug therapy)